Brought to you by 
MTTI licenses cell-sensing technology from Notre Dame
26 Mar 2010
Executive Summary
Molecular Targeting Technologies Inc. (MTTI; developing small molecules for imaging of cardiovascular diseases and cancer) has licensed exclusive rights to a cell-sensing technology designed by the University of Notre Dame's professor Bradley Smith, PhD.
Deal Industry
- Biotechnology
- Pharmaceuticals
- Research, Analytical Equipment & Supplies
-
Pharmaceuticals
- Radiopharmaceuticals, Contrast Agents
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
MTTI licenses cell-sensing technology from Notre Dame
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice